不同种的灵芝醇提物对肝癌细胞增殖的抑制作用
|
摘要
为探讨7种不同种的灵芝中三萜及甾醇含量及子实体醇提物对人肝癌细胞HepG2和SMMC-7721增殖的抑制作用,采用紫外-可见分光光度法测定三萜及甾醇含量,采用3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)法测定不同种的灵芝子实体醇提物对肝癌细胞增殖的抑制效果。结果表明:松杉灵芝(Ganoderma tsugae)、黄边灵芝(G.luteomarginatum)、赤芝(G.lucidum)、紫芝(G.sinense)、无柄灵芝(G.resinaceum)、无柄紫灵芝(G.mastoporum)、皱盖假芝(Amauroderma rude)三萜及甾醇含量依次降低,除无柄紫灵芝和皱盖假芝外,其余5种的含量均符合《中华人民共和国药典》的要求;7种灵芝的子实体醇提物均具有抑制HepG2细胞增殖的作用,半抑制率(IC_(50))分别为102.12、143.84、92.17、121.11、92.74、163.11、40.25μg/mL;对于SMMC-7721细胞,除皱盖假芝具有较小的抑制作用外,IC_(50)为166.21μg/mL,其余6种均无明显的抑制作用。7个种中皱盖假芝对肝癌细胞增殖的抑制作用效果最好,但其三萜及甾醇含量却最低,因此推测皱盖假芝的抗肿瘤活性成分可能除三萜及甾醇外还包含其它成分。
Total triterpenoids and sterols in seven Ganodermataceae species were determined using a UV spectrophotometer and their cytotoxicity against human hepatoma cell lines HepG2 and SMMC-7721 were investigated by the MTT method.The results showed that the total triterpenoids and sterols content in these species successively decreased in the order of Ganoderma tsugae,G.luteomarginatum,G.lucidum,G.masinense,G.resinaceum,G.mastoporum,and Amauroderma rude.Except G.mastoporum and A.rude,all the other five species were accorded with the stipulations in the Chinese Pharmacopoeia(2015 ed.).The ethanol extracts from all seven species showed cytotoxicity against the HepG2 cell line,with IC_(50) values of 102.12μg/mL,143.84μg/mL,92.17μg/mL,121.11μg/mL,92.74μg/mL,163.11μg/mL,and40.25μg/mL for G.tsugae,G.luteomarginatum,G.lucidum, G. masinense, G.resinaceum,G.mastoporum,and A.rude,respectively.On the other hand,none studied species but A.rude showed cytotoxicity against SMMC-7721 cells(IC_(50):166.21μg/mL).Since A.rude contained the least tested compounds but the greatest cytotoxicity against the two hepatoma cancer cell lines among all seven species,there may be other active ingredients contributing to the observed inhibitory activity against the human hepatoma cell lines.These results raised a new direction for the antitumor research of A.rude.
Total triterpenoids and sterols in seven Ganodermataceae species were determined using a UV spectrophotometer and their cytotoxicity against human hepatoma cell lines HepG2 and SMMC-7721 were investigated by the MTT method.The results showed that the total triterpenoids and sterols content in these species successively decreased in the order of Ganoderma tsugae,G.luteomarginatum,G.lucidum,G.masinense,G.resinaceum,G.mastoporum,and Amauroderma rude.Except G.mastoporum and A.rude,all the other five species were accorded with the stipulations in the Chinese Pharmacopoeia(2015 ed.).The ethanol extracts from all seven species showed cytotoxicity against the HepG2 cell line,with IC_(50) values of 102.12μg/mL,143.84μg/mL,92.17μg/mL,121.11μg/mL,92.74μg/mL,163.11μg/mL,and40.25μg/mL for G.tsugae,G.luteomarginatum,G.lucidum, G. masinense, G.resinaceum,G.mastoporum,and A.rude,respectively.On the other hand,none studied species but A.rude showed cytotoxicity against SMMC-7721 cells(IC_(50):166.21μg/mL).Since A.rude contained the least tested compounds but the greatest cytotoxicity against the two hepatoma cancer cell lines among all seven species,there may be other active ingredients contributing to the observed inhibitory activity against the human hepatoma cell lines.These results raised a new direction for the antitumor research of A.rude.
引文
[1]尚志军.神农本草经校注[M].北京:学苑出版社,2008.
[2]吴兴亮,宋斌,赵友兴,等.中国药用灵芝及名称使用商榷[J].贵州科学,2013,31(1):1-17.
[3]孙晓生.《道藏》九大仙草及其现代研究[J].新中医,2012,44(9):124-126.
[4]邓海林,吴佩颖,王建新.灵芝的研究进展[J].时珍国医国药,2005,16(2):141-143.
[5]叶鹏飞,张美萍,王康宇,等.灵芝主要成分及其药理作用的研究进展综述[J].食药用菌,2013,21(3):158-161.
[6]唐庆九,季哲,郝瑞霞,等.灵芝中性三萜类成分的抗肿瘤作用[J].食用菌学报,2010,17(1):60-64.
[7]张淑香,王萌影,刘学伟,等.复方灵芝降糖胶囊大鼠给药长期毒性研究[J].中国实验方剂学杂志,2015,21(17):146-151.
[8]李学敏,武强,席小平,等.破壁灵芝孢子油急性毒性与致突变性的研究[J].中国药物与临床,2006,6(2):108-110.
[9]吴兴亮,戴玉成.中国灵芝图鉴[M].北京:科学出版社,2005.
[10]国家药典委员会.中华人民共和国药典[M].一部.北京:中国医药科技出版社,2015.
[11]陈体强,李开本.中国灵芝科真菌资源分类、生态分布及其合理开发利用[J].江西农业大学学报,2004,26(1):89-95.
[12]戴玉成,曹云,周丽伟,等.中国灵芝学名之管见[J].菌物学报,2013,32(6):947-952.
[13]赵继鼎,徐连旺,张小青.中国灵芝亚科的分类研究[J].微生物学报,1979,19(3):265-279.
[14]刘新民,刘福平,林耀辉,等.灵芝在医药保健品上的应用[J].亚热带植物科学,1991,20(2):48-50.
[15]李向敏.皱盖假芝和灵芝孢子中甾醇类化合物抗肿瘤作用机制研究[D].广州:华南理工大学,2015.
[2]吴兴亮,宋斌,赵友兴,等.中国药用灵芝及名称使用商榷[J].贵州科学,2013,31(1):1-17.
[3]孙晓生.《道藏》九大仙草及其现代研究[J].新中医,2012,44(9):124-126.
[4]邓海林,吴佩颖,王建新.灵芝的研究进展[J].时珍国医国药,2005,16(2):141-143.
[5]叶鹏飞,张美萍,王康宇,等.灵芝主要成分及其药理作用的研究进展综述[J].食药用菌,2013,21(3):158-161.
[6]唐庆九,季哲,郝瑞霞,等.灵芝中性三萜类成分的抗肿瘤作用[J].食用菌学报,2010,17(1):60-64.
[7]张淑香,王萌影,刘学伟,等.复方灵芝降糖胶囊大鼠给药长期毒性研究[J].中国实验方剂学杂志,2015,21(17):146-151.
[8]李学敏,武强,席小平,等.破壁灵芝孢子油急性毒性与致突变性的研究[J].中国药物与临床,2006,6(2):108-110.
[9]吴兴亮,戴玉成.中国灵芝图鉴[M].北京:科学出版社,2005.
[10]国家药典委员会.中华人民共和国药典[M].一部.北京:中国医药科技出版社,2015.
[11]陈体强,李开本.中国灵芝科真菌资源分类、生态分布及其合理开发利用[J].江西农业大学学报,2004,26(1):89-95.
[12]戴玉成,曹云,周丽伟,等.中国灵芝学名之管见[J].菌物学报,2013,32(6):947-952.
[13]赵继鼎,徐连旺,张小青.中国灵芝亚科的分类研究[J].微生物学报,1979,19(3):265-279.
[14]刘新民,刘福平,林耀辉,等.灵芝在医药保健品上的应用[J].亚热带植物科学,1991,20(2):48-50.
[15]李向敏.皱盖假芝和灵芝孢子中甾醇类化合物抗肿瘤作用机制研究[D].广州:华南理工大学,2015.